# US 11,103,573 B2 · Vaccine against infectious bronchitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,103,573 B2
- Document ID: US11103573B2
- Status: Granted
- Kind: B2
- Application number: 16/309,216
- Filed: 2017-05-31
- Published: 2019-08-08
- Granted: 2021-08-31
- Earliest claimed: 2016-06-02
- Assignees: Zoetis Services LLC
- Applicants: Zoetis Services LLC
- Inventors: Carla Maria Batista de Freitas; Maria Carolina Ferreira dos Santos; Paul Joseph Dominowski; Harmen Jacob Geerligs
- Web page: https://patentgrep.com/patent/US11103573B2

## CPC

- A61K 39/155: Paramyxoviridae, e.g. parainfluenza virus
- A61K 39/12: Viral antigens
- A61K 39/15: Reoviridae, e.g. calf diarrhea virus
- A61K 39/17: Newcastle disease virus
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 39/265: Infectious rhinotracheitis virus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2720/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2720/12234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Poultry vaccines against infectious bronchitis and Turkey Rhinotracheitis are provided. The vaccines are adjuvanted with oil emulsion containing an immunostimulatory oligonucleotide. The methods of using the vaccines are also provided.

## Claims

### Claim 1

A vaccine comprising an antigen component and an adjuvant component, wherein the adjuvant component comprises an immunostimulatory oligonucleotide and a water-in-oil emulsion, and wherein the antigen component comprises an Infectious Bursal Disease (IBD) antigen, present in the amount of 107.5-108 TCID50 per dose, wherein further the adjuvant component consists essentially of the immunostimulatory oligonucleotide, the oil, and one or more emulsifiers.

### Claim 2 (depends on 1)

The vaccine of claim 1, wherein said IBD antigen is an inactivated Lukert strain antigen.

### Claim 3 (depends on 1)

The vaccine of claim 1, wherein the water-in-oil emulsion comprises a light mineral oil.

### Claim 4 (depends on 2)

The vaccine of claim 2, wherein the antigen component further comprises at least one of:
a) an antigen derived from a non-Lukert strain of IBD;
b) an Infectious bronchitis antigen;
c) a reovirus antigen;
d) a Newcastle disease antigen;
e) a Turkey rhinotracheitis antigen.

### Claim 5 (depends on 4)

The vaccine of claim 4, wherein the Infectious bronchitis antigen comprises an inactivated infectious bronchitis virus, the reovirus antigen comprises an inactivated Reovirus, the antigen derived from non-Lukert strain of IBD comprises an inactivated IBD virus of a non-Lukert strain, the Newcastle disease antigen comprises an inactivated Newcastle virus, and the Turkey rhinotracheitis antigen comprises an inactivated Turkey Rhinotracheitis virus.

### Claim 6 (depends on 1)

The vaccine of claim 1 wherein said oil emulsion is a water-in-oil (W/O) emulsion.

### Claim 7 (depends on 1)

The vaccine of claim 1 wherein said oil emulsion comprises mineral oil.

### Claim 8 (depends on 1)

The vaccine of claim 1, wherein said immunostimulatory oligonucleotide comprises SEQ ID NO: 8.

### Claim 9 (depends on 1)

The vaccine of claim 1, wherein the immunostimulatory oligonucleotide is present in the amount of 2.5-20 μg per dose.